| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
NADPH tetracyclohexanamine targets numerous enzymes that require NADPH as a cofactor. It is an essential electron donor for reductive biosynthesis (fatty acids, cholesterol, nucleotides) and antioxidant defense (glutathione reductase, thioredoxin reductase). It also serves as a cofactor for cytochrome P450 enzymes and nitric oxide synthase. The tetracyclohexanamine salt form enhances the compound's stability and solubility. |
|---|---|
| ln Vitro |
In vitro, NADPH tetracyclohexanamine is used as a cofactor in enzymatic assays and cell-free systems. It is an endogenous inhibitor of ferroptosis and plays a vital role in the biosynthesis of fatty acids and biopolymers. The compound is also required for lipid biosynthesis, biomass formation, and cell replication. Its activity as a reducing agent has been characterized in various biochemical assays.
|
| ln Vivo |
In vivo, NADPH is essential for numerous metabolic processes, including fatty acid biosynthesis, cholesterol synthesis, and antioxidant defense. The NADP⁺/NADPH redox pair facilitates electron transfer in anabolic reactions and protects against reactive oxygen species accumulation. The tetracyclohexanamine salt is used in research to study NADPH-dependent processes in animal models.
|
| Enzyme Assay |
For in vitro enzyme assays, NADPH tetracyclohexanamine is used as a cofactor for NADPH-dependent enzymes. The enzyme is incubated with the substrate and varying concentrations of NADPH tetracyclohexanamine in a suitable buffer. Enzyme activity is measured by monitoring the consumption of NADPH (absorbance at 340 nm) or the production of the reaction product using spectrophotometric or fluorometric methods.
|
| Cell Assay |
For in vitro cell-based assays, NADPH tetracyclohexanamine is typically used to supplement cell culture media for NADPH-dependent studies. Cells are treated with the compound at various concentrations (typically 0.1-10 mM) for 1-24 hours. Cellular NADPH levels are measured using enzymatic cycling assays or LC-MS. Oxidative stress markers are assessed using fluorescent probes. Lipid biosynthesis can be measured by incorporating radiolabeled acetate.
|
| Animal Protocol |
For in vivo animal experiments, NADPH tetracyclohexanamine is typically administered intraperitoneally or intravenously to rodents. The compound is given at doses ranging from 10-100 mg/kg. Blood and tissue samples are collected to measure NADPH levels and redox status. The compound's effects on lipid biosynthesis, antioxidant defense, and other NADPH-dependent processes can be evaluated.
|
| ADME/Pharmacokinetics |
NADPH tetracyclohexanamine has a molecular weight of 1142.12 g/mol and formula C₄₅H₈₂N₁₁O₁₇P₃. The tetracyclohexanamine salt form is stable and soluble in aqueous solutions. The compound is typically stored at 4°C in a sealed container away from moisture. Its pharmacokinetics are determined by the stability and distribution of the NADPH molecule itself.
|
| Toxicity/Toxicokinetics |
Toxicological data for NADPH tetracyclohexanamine are limited. As an endogenous cofactor, NADPH is non-toxic at physiological concentrations. The tetracyclohexanamine salt may have different toxicity profiles, but comprehensive studies have not been reported. The compound is classified as a research-grade reagent and is not for human therapeutic use. Standard laboratory safety practices should be followed when handling.
|
| Additional Infomation |
NADPH tetracyclohexanamine is a research-use only compound and has not been approved for clinical applications. It is also known as β-NADPH and TPNH. Its molecular weight is 1142.12, and its formula is C₄₅H₈₂N₁₁O₁₇P₃. The compound is used as a cofactor in biochemical assays and as a research tool to study NADPH-dependent metabolic processes. It is available from various research chemical suppliers.
|
| Molecular Formula |
C21H30N7O17P3.4[C6H13N]
|
|---|---|
| Molecular Weight |
1142.11748
|
| Exact Mass |
1141.51
|
| Elemental Analysis |
C, 47.32; H, 7.24; N, 13.49; O, 23.81; P, 8.14
|
| CAS # |
100929-71-3
|
| Related CAS # |
NADPH tetrasodium salt;2646-71-1
|
| PubChem CID |
71312102
|
| Appearance |
White to light yellow solid powder
|
| LogP |
6.562
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
76
|
| Complexity |
1450
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
NC1=C2C(N([C@H]3[C@H](OP(O)(O)=O)[C@H](O)[C@@H](COP(OP(O)(OC[C@@H]4[C@@H](O)[C@@H](O)[C@H](N5C=C(C(N)=O)CC=C5)O4)=O)(O)=O)O3)C=N2)=NC=N1.NC6CCCCC6.NC7CCCCC7.NC8CCCCC8.NC9CCCCC9
|
| InChi Key |
PTKRUDMLGIIORX-ITGWJZMWSA-N
|
| InChi Code |
InChI=1S/C21H30N7O17P3.4C6H13N/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32;4*7-6-4-2-1-3-5-6/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35);4*6H,1-5,7H2/t10-,11-,13-,14-,15-,16-,20-,21-;;;;/m1..../s1
|
| Chemical Name |
[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;cyclohexanamine
|
| Synonyms |
Dihydronicotinamide-adenine dinucleotide phosphate; cyclohexyl ammonium salt; NADPH cyclohexyl ammonium salt; NADPH Cy4N
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥100 mg/mL (~87.6 mM)
DMSO: ≥84 mg/mL (`73.6 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8756 mL | 4.3778 mL | 8.7556 mL | |
| 5 mM | 0.1751 mL | 0.8756 mL | 1.7511 mL | |
| 10 mM | 0.0876 mL | 0.4378 mL | 0.8756 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
